Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Employing the new cell line, NUE-1, which was derived from cells of ascites in a woman with endometrial carcinoma, the sensitivity test for anticancer agents was carried out in culture and xenografts in nude mice. Anticancer activity in vitro was evaluated by counting surviving cells, and the therapeutic index was expressed by LD50 for mice/MLD90 in vitro. NUE-1 cells were inoculated subcutaneously in BALB/c nude mice, and then tumors serially transplanted were used as materials. Anticancer agents (ADM, CDDP, CHA3, CQ, MMC) at 1/3 LD50 dosage for mice were administered intraperitoneally on a schedule of 3 doses for every 4 days. The results were as follows: The therapeutic index of ADM was highest at five to nineteen times the others In vivo, ADM demonstrated + activity, whereas others had no significant effect There was a close correlation between the therapeutic index and in vivo anticancer effect using nude mice.
 ...
PMID:Efficacy of anticancer agents in vitro and in vivo using cultured human endometrial carcinoma cells--study of therapeutic index. 310 52

We conducted a joint phase II study in 76 patients with gynecological cancer (42 patients with ovarian cancer, 22 patients with cervical cancer, 10 patients with endometrial cancer and 2 patients with vaginal cancer). The response rate was 25.0% in the patients with ovarian cancer, 13.3% in those with cervical cancer, and 28.6% in those with endometrial cancer. The overall response rate was 23.1%. When the patients were classified according to dose schedules, the highest response rate was obtained in the group administered THP-ADM at a dose of 60 mg per body by single i.v. injection at 3-week intervals. Such side effects as myelosuppression and gastrointestinal disturbances were observed, but alopecia, a marked side-effect of ADM administration, was mild, and no cardiac toxicity was seen in any of the patients.
 ...
PMID:[Phase II study of 4'-O-tetrahydropyranyl-adriamycin (THP-ADM) in patients with gynecological cancer]. 405 11

4'-0-tetrahydropyranyladriamycin hydrochloride (THP-ADM) is a new anthracycline derivative. The antitumor activity of THP-ADM was tested on 51 human tumor samples representing ten different tumor types in in vitro colony assay method. Tested tumors were: 26 cases of ovarian cancer, 8 cases of breast cancer, 6 cases of colorectal cancer, 3 cases of endometrial cancer, 2 cases each with gastric cancer and sarcoma, and another 4 cases. An in vitro colony assay was done in soft agar as described by Hamburger & Salmon. The criteria for in vitro sensitivity was defined as a 70 percent or greater reduction in the number of colonies after a 1-h exposure to drugs. The selected concentrations of THP-ADM for assay were 0.05, 0.5, and 1.0 micrograms/ml. The sensitivity rates for THP-ADM in each dose were: 0.05 micrograms/ml (7/19, 37%), 0.5 micrograms/ml (10/51, 20%), and 1.0 micrograms/ml (12/19, 63%). In vitro sensitivity of adriamycin (0.04 micrograms/ml) was simultaneously tested in 49 cancer patients. Five out of 25 ovarian cancer patients (20%) showed responses to adriamycin and an overall response rate was 12% (6/49). These data indicate that THP-ADM has an antitumor activity against various cancers and it is comparable to that of adriamycin.
 ...
PMID:Activity of 4'-0-tetrahydropyranyladriamycin hydrochloride (THP-ADM) in a human tumor cloning system. 668 22

We experienced a case of histological complete remission by preoperative intraarterial infusion chemotherapy in the treatment of histologically diagnosed endometrial cancer of well differentiated type. MRI demonstrated invasion of the myometrium to a depth of more than 1/2 and left partial parametrium. This patient was given intra-uterine arterial infusion chemotherapy twice (CDDP & ADM ia, CPA iv). Radical hysterectomy was done 3 weeks after intraarterial infusion chemotherapy. The extirpated uterus was histologically complete remission. Thus, in this case shows that intraarterial infusion chemotherapy is effective for neo-adjuvant chemotherapy of endometrial cancer.
 ...
PMID:[A case of histological complete remission by preoperative intraarterial infusion chemotherapy]. 757 97

Intraperitoneal and arterial neo-adjuvant chemotherapy were given to one patient with endometrial carcinoma (clear cell adenocarcinoma). She was diagnosed as an inoperable advanced carcinoma (stage IV B) associated with direct invasion of the urinary bladder and pleural effusion. Intraperitoneal infusion therapy with CDDP 100 mg was given every 3 weeks. The patient was also given intra-uterine arterial infusion chemotherapy three times with CDDP and ADM. MRI, CT, and Cystoscopic examinations failed to detect any carcinoma. An optimal operation was performed. In a histological study, the uterine carcinoma was in complete remission. But a degenerative adenocarcinoma was shown at peritoneal dissemination.
 ...
PMID:[A case report: endometrial carcinoma response to intraperitoneal and intraarterial chemotherapy]. 970 19

Recently, the number of cases of endometrial cancer has increased in Japan. Most of the increase are accounted for by premenopausal cases, which are frequently positive for ER or PR. Hormonal treatment using progestins such as MPA has been widely applied to endometrial cancer patients under 40 years old under the conditions of grade 1 well-differentiated endometrioid adenocarcinoma without myometrial invasion. In our hospital, we applied high-dose (600 mg/day) MPA for over 8 weeks in 14 cases of endometrial cancer, of which adenocarcinoma disappeared in 12 cases (86%), followed by cyclic administrations of low-dose MPA, with 7 subsequent recurrences. We think that a protocol for improving ovarian function, such as active induction of ovulation, should be established to induce intrinsic progesterone sufficient for the prevention of the recurrence of endometrial cancers. In the 2 cases, in which adenocarcinoma remained even after long administrations of MPA, myometrial invasion was noted in the surgically resected specimens. For advanced or recurrent endometrial cancers, MPA has been reported to be effective in an average of 26% in several reports, and effective in 42% cases when applied with combination chemotherapy, such as CAP, by virtue of the "chemical modulator" effect, which can delay the acquired resistance against ADM or CDDP. Furthermore, MPA has resulted in a significant improvement of 5-year disease-free survival rate when used as adjuvant therapy after complete operations and whole pelvic irradiation, compared with administrations of 5-FU in a randomized controlled study in Japan. Thus, in the future, we consider that hormonal therapy will play a more important role in endometrial cancer treatment.
 ...
PMID:[Hormonal therapy for endometrial adenocarcinoma]. 1147 42

The role of chemotherapy for metastatic endometrial carcinoma is palliation, although modest response can be achieved because of development of chemotherapy. The response rate is 31-56% of conventional CAP therapy and 33-81% of AP therapy. However these chemotherapeutic regimen did not prolong the survival. Recently, a randomized trial of TAP therapy (TXL 160 mg/m2 3 h, day 2, ADM 45 mg/m2, day 1, CDDP 50 mg/m2 day 1) versus AP therapy (ADM 60 mg/m2, CDDP 50 mg/m2) was reported. The response and survival of TAP is superior to that of AP. Taxane will be key drugs for chemotherapy of endometrial cancer in the future.
 ...
PMID:[Latest information of therapeutic approach for endometrial cancer]. 1221 63

Surgery is the treatment of choice for uterine endometrial cancer. However, partial response anticancer chemotherapies for advanced cases with metastasis may also be effective. Current therapy is CAP (CDDP + ADM + CPM), which is centered on CDDP, but sufficient effect is not provided, and a new regimen is needed. We herein report a case of endometrial cancer with metastasis to the lung in which multidisciplinary treatment including taxanes was effective.
 ...
PMID:[A case of uterine endometrial cancer with lung metastases improved by various treatments including taxane]. 1293 78